By using this website, we will assume that you agree to the terms and conditions of our privacy policy. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. Shivaani Kummar, M.D., FACP Lisa M. Coussens, M.D. The Knight Cancer Institutes Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. And to train and inspire the next generation of doctors and scientists. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . . This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Charles D. Blanke, M.D., F.A.C.P., F.A.S.C.O. 12 Reviews). Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . Together they form a unique fingerprint. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. The couple says their ultimate goal is to develop new effective therapies for cancer. Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. lions led by donkeys for and against. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. These topic labels come from the works of this person. They say they shared an interest in cancer drug discovery and development that grew after their marriage. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. 2001-2022 Oregon Health & Science University. Will you join us. If you made any changes in Pure these will be visible here soon. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. OHSU is an equal opportunity affirmative action institution. We are thrilled he is able to co-lead this new venture. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . What is the importance of philanthropy to your work? Patients and Methods. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. shivaani kummar ohsu email. Administrative Coordinator, Denise Hopkins Clinical trials Drug development oncology. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. By continuing you agree to the use of cookies. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Today is a global celebration of giving an opportunity to support the causes that matter the most to you. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. 11 Jun 2022. This center will be for the community, and we hope people will reach out to be a part of it. The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. What excites you about coming to work in the morning? Notice of Privacy Practices The new early-phase research unit completes this expansion in the building. (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . Recent external collaboration on country/territory level. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Administrative Coordinator, Margaret Rogers Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Dr. Kummar completed a residency at Emory University. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. middlesex county community college nursing program nj The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. 2001-2022 Oregon Health & Science University. We have a billion reasons why you should join us. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Together they have built a strong record of discovery, innovation and care. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . This philanthropy-fueled research revolution is already saving lives. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. Uncategorized . We have a number of clinical trials investigating promising new strategies to treat cancer. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS.
Dishwasher Leaking From Soap Dispenser,
Houses For Rent In Burlington Colorado,
Manchester Ao Arena Seating Plan Rows,
Is Bradley Walsh Catholic,
Articles S